These differences of action between ERRα inhibition in breast cancer and hepatocarcinoma could be explained by a tissue-specific effect or acute loss (pharmacological) versus the chronic loss (knockout mice) of ERRα. This evidence concerns the gene ESRRA and breast cancer.